GLENMARK.NS Balance Sheet
Glenmark Pharmaceuticals Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 22:31
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹3,904.16 Cr. | ₹3,118.15 Cr. | ₹3,319.37 Cr. | ₹3,889.57 Cr. | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹1,115.18 Cr. | ₹419.32 Cr. | ₹541.99 Cr. | ₹427.87 Cr. | CapitalWorkInProgress |
| Goodwill | ₹73.62 Cr. | ₹67.36 Cr. | ₹70.27 Cr. | ₹82.86 Cr. | Goodwill |
| Other Intangible Assets | ₹2,224.61 Cr. | ₹1,024.65 Cr. | ₹1,097.19 Cr. | ₹1,942.11 Cr. | OtherIntangibleAssets |
| Non-current Investments | ₹44.65 Cr. | ₹789.66 Cr. | ₹56.35 Cr. | ₹42.36 Cr. | NoncurrentInvestments |
| Other Non-current Assets | ₹153.86 Cr. | ₹149.23 Cr. | ₹179.03 Cr. | ₹428.00 Cr. | OtherNoncurrentAssets |
| Total Non-current Assets | ₹9,497.96 Cr. | ₹6,930.54 Cr. | ₹6,754.09 Cr. | ₹8,608.17 Cr. | NoncurrentAssets |
| Inventories | ₹2,977.79 Cr. | ₹2,513.05 Cr. | ₹3,028.53 Cr. | ₹3,430.78 Cr. | Inventories |
| Trade Receivables | ₹4,098.61 Cr. | ₹1,858.41 Cr. | ₹3,341.95 Cr. | ₹4,963.35 Cr. | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹1,443.03 Cr. | ₹1,658.27 Cr. | ₹1,675.71 Cr. | ₹1,174.71 Cr. | CashAndCashEquivalents |
| Current Investments | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | CurrentInvestments |
| Other Current Assets | ₹1,153.62 Cr. | ₹1,223.57 Cr. | N/A | ₹1,504.60 Cr. | OtherCurrentAssets |
| Total Current Assets | ₹9,873.72 Cr. | ₹7,428.08 Cr. | ₹9,295.47 Cr. | ₹11,299.71 Cr. | CurrentAssets |
| Total Assets | ₹19,371.68 Cr. | ₹14,358.62 Cr. | ₹16,049.55 Cr. | ₹19,907.88 Cr. | Assets |
| Equity Share Capital | ₹28.22 Cr. | ₹28.22 Cr. | ₹28.22 Cr. | ₹28.22 Cr. | EquityShareCapital |
| Other Equity | ₹9,445.71 Cr. | ₹7,819.71 Cr. | ₹8,821.22 Cr. | ₹10,483.89 Cr. | OtherEquity |
| Equity Attributable to Owners | ₹9,473.92 Cr. | ₹7,847.93 Cr. | ₹8,849.44 Cr. | ₹10,512.11 Cr. | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | ₹365.34 Cr. | ₹-0.38 Cr. | ₹-0.37 Cr. | ₹-0.32 Cr. | NonControllingInterest |
| Total Equity | ₹9,839.26 Cr. | ₹7,847.55 Cr. | ₹8,849.07 Cr. | ₹10,511.79 Cr. | Equity |
| Long-term Borrowings | ₹3,852.14 Cr. | ₹0.00 Cr. | ₹512.70 Cr. | ₹0.00 Cr. | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹4,486.89 Cr. | ₹692.49 Cr. | ₹1,233.46 Cr. | ₹3,019.66 Cr. | NoncurrentLiabilities |
| Short-term Borrowings | ₹495.58 Cr. | ₹990.60 Cr. | ₹1,681.49 Cr. | ₹0.00 Cr. | BorrowingsCurrent |
| Trade Payables | ₹2,391.86 Cr. | ₹2,535.93 Cr. | ₹2,579.53 Cr. | ₹3,743.87 Cr. | TradePayablesCurrent |
| Other Current Liabilities | ₹194.81 Cr. | ₹244.36 Cr. | ₹199.00 Cr. | ₹862.12 Cr. | OtherCurrentLiabilities |
| Total Current Liabilities | ₹5,045.53 Cr. | ₹5,818.59 Cr. | ₹5,967.02 Cr. | ₹6,376.43 Cr. | CurrentLiabilities |
| Total Equity and Liabilities | ₹19,371.68 Cr. | ₹14,358.62 Cr. | ₹16,049.55 Cr. | ₹19,907.88 Cr. | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from GLENMARK.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).